Longevity & AgingForschungsarbeitKostenpflichtig

Glaucoma Review Links Eye Disease to Brain Neurodegeneration and Maps Emerging Therapies

A neurology handbook chapter reviews glaucoma diagnosis, pressure-lowering treatments, and emerging stem cell, gene, and AI approaches, tying the eye to the brain.

Montag, 16. November 2026 1 Aufruf
Veröffentlicht in Handb Clin Neurol
Close-up of a human eye undergoing optical coherence tomography scan, with glowing retinal layers and optic nerve head visible

Zusammenfassung

Glaucoma is a leading cause of blindness. It is a group of optic neuropathies in which retinal ganglion cells degenerate. This handbook chapter reviews how glaucoma is classified, mainly by whether the drainage angle of the eye is open or closed, and why the chronic form, which progresses silently, makes regular eye exams essential. Key tools include ophthalmoscopy, gonioscopy, tonometry, optical coherence tomography, and visual field testing. Because most cases involve raised intraocular pressure from poor fluid drainage, treatments (drops, laser, surgery) aim to lower that pressure. The chapter summarizes landmark clinical trials behind current practice and previews emerging work in stem cells, gene therapy, visual prostheses, and AI. It also argues neurologists should know glaucoma because it shares features with other neurodegenerative diseases and affects both eye and brain.

0:00--:--

Detaillierte Zusammenfassung

Glaucoma is a major cause of irreversible blindness, and because the common chronic form progresses without early symptoms, many people lose vision before diagnosis. For aging adults and the clinicians who care for them, understanding how it is detected and managed is directly relevant to preserving function and independence.

This chapter, written for a clinical neurology handbook, is a narrative review rather than a new study. It describes glaucoma as a group of optic neuropathies marked by degeneration of retinal ganglion cells, classified mainly by the anatomy of the anterior chamber angle (open versus closed) and then by cause and time course.

The authors outline the core evaluation toolkit: ophthalmoscopy to inspect the optic nerve head, gonioscopy to view the drainage angle, tonometry to measure intraocular pressure, optical coherence tomography to image structural damage to the optic nerve head, macula, and retinal nerve fiber layer, and perimetry to test visual function. Since most glaucoma involves elevated pressure from impaired aqueous humor outflow, current treatments (medications, laser, and surgery) all focus on lowering that pressure. The chapter also summarizes major clinical trials that shaped standard practice.

Looking forward, it surveys emerging approaches including stem cell therapies, gene therapies, visual prostheses, and artificial intelligence and computer vision. The authors emphasize that glaucoma shares pathophysiologic features with other neurodegenerative conditions and affects both eye and brain, so neurologists should be familiar with it.

Caveats: only the abstract was available, so specific trial results, effect sizes, and the depth of evidence for emerging therapies cannot be assessed here. The emerging technologies are described as promising, not proven, and this summary cannot confirm clinical readiness.

Wichtigste Erkenntnisse

  • Glaucoma is a group of optic neuropathies causing retinal ganglion cell degeneration and is a prevalent cause of blindness.
  • Chronic glaucoma is the most common type and progresses insidiously, making periodic eye exams critical.
  • Core assessment uses ophthalmoscopy, gonioscopy, tonometry, optical coherence tomography, and perimetry.
  • All current treatments (medications, laser, surgery) work by lowering intraocular pressure.
  • Emerging research includes stem cell therapy, gene therapy, visual prosthesis, and AI/computer vision.

Methodik

This is a narrative review chapter in the Handbook of Clinical Neurology, not a primary study. It synthesizes classification, diagnostic modalities, treatments, landmark clinical trials, and emerging research. Based on the abstract only; no methods for literature selection are described.

Studienlimitierungen

Only the abstract was available, so details on trial findings, quantitative outcomes, and evidence quality are unknown. As a narrative review, it may reflect author selection bias. Emerging therapies are described as promising and remain largely investigational.

Hat dir diese Zusammenfassung gefallen?

Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.

E-Mail-Adresse zum Abonnieren eingeben: